when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Jul 20, 26Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharma dive

Jul 20, 26STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputerstat

Jul 20, 26Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsfiercebiotech

Jul 20, 26STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers saystat

Jul 20, 26Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independencebiospace

Jul 18, 26‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsfiercebiotech

Jul 17, 26STAT+: The end for GSK’s chronic cough treatmentstat

Jul 17, 26Compounders maintain a firm grip on the GLP-1 marketbiopharma dive

Jul 17, 26STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and morestat

Jul 17, 26Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hireendpoints

Jul 17, 26STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claimsstat

Jul 16, 26Predicting biotech clinical trials and a new Alzheimer’s drug controversystat

Jul 16, 26Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsbiopharma dive

Jul 16, 26Veradermics keeps ‘momentum going’ as baldness drug helps women with hair lossbiopharma dive

Jul 16, 26STAT+: Brain implant restores the sensation of touch in a person with quadriplegiastat

Jul 16, 26Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeoverbiospace

Jul 16, 26STAT+: FDA approves Merck’s oral PCSK9 drug, a firststat

Jul 16, 26Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immunobiospace

Jul 16, 26STAT+: Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvalsstat

Jul 16, 26STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckleystat

Jul 16, 26Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyendpoints

Jul 15, 26Eli Lilly invests in Oura to support patients on GLP-1 drugsendpoints

Jul 15, 26J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsbiopharma dive

Jul 15, 26STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and morestat

Jul 14, 26STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and morestat

Jul 14, 26Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsbiopharma dive

Jul 11, 26Deals, deals, deals; Biohaven takes on Eli Lilly; and moreendpoints

Jul 10, 26STAT+: Pharmalittle: We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and morestat

Jul 9, 26Whistleblower takes on health insurance and FDA commissioner candidatesstat

Jul 9, 26Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downendpoints

← prevpage 16 of 21next →